Skip to main content

300 Collins St Melbourne hello@pivot.net

Main navigation

About
Research & Development
Pipeline
Investors
Careers

Targeting KRAS-G12C and Beyond

April 9, 2022

Elena S. Koltun

American Association for Cancer Research (AACR) Annual Meeting 2022; April 8-13, 2022

Download presentation

Return to Media Home

Latest Scientific Presentations

Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS

Optimizing RAS Inhibition with Dual Blockade of Oncogenic and Wild-Type RAS

Combinations of Tri-complex KRAS(ON) Inhibitors with RAS Companion Inhibitors and Immunotherapies Improve Anti-tumor Activity and Abrogate Adaptive Resistance in Preclinical Tumor Models In Vivo

Bi-steric mTORC1 inhibitors are superior to rapamycin and induce apoptotic cell death in tumor models with hyperactivated mTORC1

RMC-0708 (RM-046), a first-in-class, mutant-selective and oral KRASQ61H(ON) inhibitor that drives tumor regression in preclinical models and validates KRASQ61H as a therapeutic target

© Revolution Medicines, Inc. | 700 Saginaw Drive, Redwood City, CA 94063
CCPA Notice | Privacy Policy

Get in touch with us